Company: SMNR
Filing Date: 2025-09-26
Form Type: 8-K
Source: 0001193125-25-220455
Chunk: 4

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-09-26
Form: 8-K
Item: Item 5.01
Chunk 4
---
Item 5.01.      Changes in Control of Registrant.  

Reference is made to the disclosure in the Proxy Statement/Prospectus in the section titled “ Proposal 1 - The Business Combination Proposal,” which is incorporated herein by reference. Further reference is made to the information contained in Item 2.01 of this Current Report, which is incorporated herein by reference.

  Item 5.02.      Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.  

The information contained in the sections titled “ Form 10 Information - Directors and Executive Officers,” “Form 10 Information - Executive Compensation,” “Form 10 Information - Director Compensation,” “Form 10 Information - Certain Relationships and Related Party Transactions” and “Form 10 Information - Indemnification of Directors and Officers” in Item 2.01 of this Current Report is incorporated herein by reference.

Effective as of the Closing, the following people were appointed as directors of the Company:

  Class I director: Jay Chun, M. D., Ph. D. and Annu Navani, M. D.;  

  Class II directors: Dorman Followwill and Yue Alexander Wu, Ph. D.; and  

  Class III directors: Henry Ji, Ph. D. and Jaisim Shah.  

Effective as of the Closing, the executive officers of the Company are:

  Jaisim Shah, Chief Executive Officer and President;  

  Henry Ji, Ph. D., Executive Chairperson; and  

  Stephen Ma, Chief Financial Officer, Senior Vice President and Secretary.  

In addition to the information described below regarding the appointment of Annu Navani to the Board and the composition of the compensation committee and nominating and corporate governance committee of the Board, reference is made to the disclosure described in the Proxy Statement/Prospectus in the section titled “ Directors and Executive Officers of New Semnur after the Business Combination” for biographical information about each of the directors and officers following the Business Combination, which is incorporated herein by reference.

Appointment of Annu Navani

Dr. Navani, age 54, founded and has served as the Chief Executive Officer of Comprehensive Spine and Sports Center since 2008 as a leader in interventional and multidisciplinary spine, musculoskeletal, and orthopedic care. She has also been serving as the Chief Medical Officer at Boomerang Healthcare since May 2022. Over the last decade, she has scaled